Hyaluronan network remodeling by ZEB1 and ITIH2 enhances the motility and invasiveness of cancer cells
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci180570 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Sieun Lee und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine and Inflammation-Cancer Microenvironment Research Center, College of Medicine, Ewha Womans University, Seoul, South …. Hauptthemen laut MEDLINE: Zinc Finger E-box-Binding Homeobox 1, Cell Movement, Hyaluronic Acid, Lung Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Health Fellowship Foundation.
Abstract (Originalsprache)
Hyaluronan (HA) in the extracellular matrix promotes epithelial-mesenchymal transition (EMT) and metastasis; however, the mechanism by which the HA network constructed by cancer cells regulates cancer progression and metastasis in the tumor microenvironment (TME) remains largely unknown. In this study, inter-α-trypsin inhibitor heavy chain 2 (ITIH2), an HA-binding protein, was confirmed to be secreted from mesenchymal-like lung cancer cells when cocultured with cancer-associated fibroblasts. ITIH2 expression is transcriptionally upregulated by the EMT-inducing transcription factor ZEB1, along with HA synthase 2 (HAS2), which positively correlates with ZEB1 expression. Depletion of ITIH2 and HAS2 reduced HA matrix formation and the migration and invasion of lung cancer cells. Furthermore, ZEB1 facilitates alternative splicing and isoform expression of CD44, an HA receptor, and CD44 knockdown suppresses the motility and invasiveness of lung cancer cells. Using a deep learning–based drug-target interaction algorithm, we identified an ITIH2 inhibitor (sincalide) that inhibited HA matrix formation and migration of lung cancer cells, preventing metastatic colonization of lung cancer cells in mouse models. These findings suggest that ZEB1 remodels the HA network in the TME through the regulation of ITIH2, HAS2, and CD44, presenting a strategy for targeting this network to suppress lung cancer progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Medicine and Inflammation-Cancer Microenvironment Research Center, College of Medicine, Ewha Womans University, Seoul, South Korea.
- Deargen Inc., Daejeon, South Korea.
- Department of Microbiology, College of Science and Technology, Dankook University, Cheonan, South Korea.
- Research Institute and Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, South Korea.
- UroGyn Efficacy Evaluation Center, Ewha Womans University Mokdong Hospital, Seoul, South Korea.
- Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Förderung
- National Research Foundation of Korea
- Health Fellowship Foundation
Zitieren
APA
Lee, S., Park, J., Cho, S., Kim, E. J., Oh, S., Lee, Y., Park, S., Kang, K., Shin, D. H., Ko, S. Y., Kurie, J. M., & Ahn, Y. H. (2025). Hyaluronan network remodeling by ZEB1 and ITIH2 enhances the motility and invasiveness of cancer cells. Journal of Clinical Investigation. https://doi.org/10.1172/jci180570
Vancouver
Lee S, Park J, Cho S, Kim EJ, Oh S, Lee Y, et al. Hyaluronan network remodeling by ZEB1 and ITIH2 enhances the motility and invasiveness of cancer cells. Journal of Clinical Investigation. 2025. doi:10.1172/jci180570
BibTeX
@article{Lee2025,
author = {Lee, Sieun and Park, Jihye and Cho, Seongran and Kim, Eun Ju and Oh, Seonyeong and Lee, Younseo and Park, Sungsoo and Kang, Keunsoo and Shin, Dong Hoon and Ko, Song Yi and Kurie, Jonathan M and Ahn, Young-Ho},
title = {Hyaluronan network remodeling by ZEB1 and ITIH2 enhances the motility and invasiveness of cancer cells},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci180570}
}
EUVIMED